Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Silence Therapeutics ( (SLN) ).
On August 11, 2025, Michael Davidson resigned from the board of directors of Silence Therapeutics plc to focus on his role as CEO of NewAmsterdam Pharma Company N.V. His departure was not due to any disagreements with the company. The board expressed gratitude for his contributions and reduced its size from five to four directors, appointing Iain Ross to fill the vacancy on the Audit and Risk Committee.
The most recent analyst rating on (SLN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Silence Therapeutics stock, see the SLN Stock Forecast page.
Spark’s Take on SLN Stock
According to Spark, TipRanks’ AI Analyst, SLN is a Neutral.
The overall score is primarily influenced by financial instability and valuation concerns, despite positive corporate governance events. Technical indicators suggest neutral momentum, but the lack of profitability and negative equity weigh heavily on the stock’s attractiveness.
To see Spark’s full report on SLN stock, click here.
More about Silence Therapeutics
Average Trading Volume: 109,983
Technical Sentiment Signal: Sell
Current Market Cap: $264M
For detailed information about SLN stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money